Who founded Bolt Biotherapeutics?

Bolt Biotherapeutics was founded by Dr. Edgar G. Engleman.

Who are Bolt Biotherapeutics's investors?

Bolt Biotherapeutics's investors include Pfizer Venture Investments, Pivotal Life Sciences, RA Capital, Samsara BioCapital, Sofinnova Ventures, Vivo Capital, Nan Fung Life Sciences, Novo Holdings and 2 more.

How much funding has Bolt Biotherapeutics raised?

Bolt Biotherapeutics has disclosed $51.9M raised across 1 of its 2 known rounds.

Where is Bolt Biotherapeutics headquartered?

Bolt Biotherapeutics is headquartered in San Francisco, US.

Bolt Biotherapeutics

NASDAQ: BOLT

San Francisco, US · 10 known investors

Find your way into Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer. The company focuses on cancer immunotherapeutics and myeloid biology to address unmet patient needs.

Biotech Healthtech Medical Devices

Founders & leadership

Dr. Edgar G. EnglemanFounder

Investors · 10

Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M

How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us

Pivotal Life Scienceslisted by Pivotal Life SciencesSan Francisco

How we know: Pivotal Life Sciences's portfolio page · the S-1 prospectus · funding news · press coverage · Not right? Tell us

RA Capitallisted by RA CapitalBoston

How we know: RA Capital's portfolio page · the S-1 prospectus · Not right? Tell us

Samsara BioCapitallisted by Samsara BioCapitalMenlo Park

How we know: Samsara BioCapital's portfolio page · Not right? Tell us

Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M

How we know: Sofinnova Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · the S-1 prospectus · funding news · Not right? Tell us

Nan Fung Life SciencesreportedHong Kong

How we know: funding news · press coverage · Not right? Tell us

Novo HoldingsreportedCopenhagen · $1.1M – $54M

How we know: the S-1 prospectus · funding news · press coverage · Not right? Tell us

Rock Springs CapitalreportedBaltimore

How we know: the S-1 prospectus · Not right? Tell us

Sofinnova Venture PartnersreportedMenlo Park

How we know: the S-1 prospectus · Not right? Tell us

Funding

SEC filings, press & company announcements

$51.9M disclosed across 1 of 2 rounds · 2019–2021

Undisclosed amountSeries BFeb 2019
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Valuation · disclosed

Disclosed events

$460.4Mvaluation at IPOFeb 2021 · $20.00/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Founder mafia

2 people who came through Bolt Biotherapeutics went on to found or lead other companies.

Brian O'CallaghanChair of the Board of DirectorsFounded Acucela Inc. +1 Bill GrossmanMember, Development Advisory BoardFounded Oncko

Competitors · 2

by search overlap

Northwest Biotherapeutics20 shared keywordsNW Bio develops personalized dendritic cell-based cancer vaccines intended to treat a range of solid tumor cancers as an alternative to chemotherapy. Its clinical-stage products target cancers including glioblastoma, inoperable solid tumors, ovarian cancer, and prostate cancer.

Bioworld19 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Bolt Biotherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Bolt Biotherapeutics do?: Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer. The company focuses on cancer immunotherapeutics and myeloid biology to address unmet patient needs.
Who founded Bolt Biotherapeutics?: Bolt Biotherapeutics was founded by Dr. Edgar G. Engleman.
Who are Bolt Biotherapeutics's investors?: Bolt Biotherapeutics's investors include Pfizer Venture Investments, Pivotal Life Sciences, RA Capital, Samsara BioCapital, Sofinnova Ventures, Vivo Capital, Nan Fung Life Sciences, Novo Holdings and 2 more.
How much funding has Bolt Biotherapeutics raised?: Bolt Biotherapeutics has disclosed $51.9M raised across 1 of its 2 known rounds.
Where is Bolt Biotherapeutics headquartered?: Bolt Biotherapeutics is headquartered in San Francisco, US.